>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
FMS样酪氨酸激酶3配体在急性髓系白血病患者血清中的表达及其临床意义
作者:宋辉  于艺冰  郭媛媛 
单位:秦皇岛市第一医院 血液内科, 河北 秦皇岛 066000
关键词:急性髓系白血病 血清 FMS样酪氨酸激酶3配体 预后 
分类号:R733.7
出版年·卷·期(页码):2021·40·第一期(41-45)
摘要:

目的:分析血清FMS样酪氨酸激酶3配体(Flt3 ligand,Flt3L)在急性髓系白血病(acute myeloid leukemia,AML)患者中的表达水平及其临床意义。方法:选取2017年10月至2019年1月本院收治的200例AML患者为研究对象,分为初治组(n=124)、缓解组(n=39)和复发组(n=37)。用酶联免疫吸附试验检测入组时血清Flt3L表达水平。对初治组患者进行为期1年的随访,根据生存预后分为存活组(n=96)和死亡组(n=28)。AML患者不良生存预后的影响因素用Cox多因素分析,采用受试者工作特征(ROC)曲线分析Flt3L预测预后的价值。结果:初治组血清Flt3L质量浓度为(83.09±12.09)pg·ml-1,复发组为(91.76±20.23)pg·ml-1,均低于缓解组的(133.08±30.24)pg·ml-1(均P<0.001),而初治组与复发组差异有统计学意义(P<0.001)。存活组血清Flt3L质量浓度为(88.07±11.82)pg·ml-1,高于死亡组的(78.07±10.09)pg·ml-1,但差异无统计学意义(t=1.372,P>0.05)。血清Flt3L (OR=0.897)是AML患者死亡的独立影响因素(P<0.05)。血清Flt3L预测AML患者1年内死亡的ROC曲线下面积(AUC)为0.823(P=0.031);当血清Flt3L截断值为75.08 pg·ml-1时,约登指数最大(0.625),此时血清Flt3L预测AML患者死亡预后的价值最高,灵敏度为84.15%,特异度为79.83%。结论:血清Flt3L对AML患者病情及预后早期评价有一定价值。

Objective: To explore the expression and significance of serum FMS like tyrosine kinase 3 ligand (Flt3L) in patients with acute myeloid leukemia (AML). Methods: 200 patients with AML admitted between October 2017 and January 2019 were included in the present study, including initial treatment group (n=124), remission group (n=39) and recurrence group (n=37). Enzyme linked immunosorbent assay (ELISA) was used to detect the expression of Flt3L in serum of all patients. According to the survival prognosis, the initial treatment group was further divided into survival group and death group, which had 96 and 28 patients respectively. Cox regression model and ROC curve were used to analyze the prognostic value of AML patients. Results: The serum Flt3L concentration in the initial treatment group was (83.09 ±12.09) pg·ml-1, and that in the recurrence group was (91.76 ±20.23) pg·ml-1, which was lower than that in the remission group (133.08 ±30.24) pg·ml-1 (P<0.001). There was statistically significant between the initial treatment group and the recurrence group (P<0.001). The serum Flt3L concentration in survival group was (88.07±11.82) pg·ml-1, which was higher than (78.07±10.09) pg·ml-1 in death group but there was no significant difference between the two groups(t=1.372,P>0.05). Serum Flt3L (OR=0.897) was an independent factor influencing the death of AML patients (P<0.05). The AUC of serum Flt3L was 0.823 (P=0.031). When the Cut-off value of serum Flt3L was 75.08 pg·ml-1, the Youden index was the highest (0.625). At this time, the value of serum Flt3L in predicting the death prognosis of AML patients was the highest, with a sensitivity of 84.15% and a specificity of 79.83%. Conclusion: Serum Flt3L is valuable for early evaluation of AML patients' condition and prognosis.

参考文献:

[1] KUYKENDALL A,DUPLOYEZ N,BOISSEL N,et al.Acute myeloid leukemia:the good,the bad,and the ugly[J].Am Soc Clin Oncol Educ Book,2018,38:555-573.
[2] 刘彦,克晓燕,王晶,等.伴FLT3-ITD突变的急性髓系白血病的临床特征和预后[J].中国实验血液学杂志,2018,26(2):354-358.
[3] 杨槟荧.FLT3-ITD和DNMT3A R882基因联合突变在急性髓系白血病中的研究进展[J].中国当代医药,2018,25(15):26-29.
[4] SAEVARSDOTTIR S,OLAFSDOTTIR T A,IVARSDOTTIR E V,et al.FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease[J].Nature,2020,584(7822):619-623.
[5] AUDIGER C,LESAGE S.FLT3 ligand is dispensable for the final stage of type 1 conventional dendritic cell differentiation[J].J Immunol,2020,128(32):111-119.
[6] TORT TARRÉS M,ASCHENBRENNER F,MAUS R,et al.The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis[J].Thorax,2019,74(10):947-957.
[7] TSAPOGAS P,MOONEY C J,BROWN G,et al.The cytokine Flt3-ligand in normal and malignant hematopoiesis[J].Int J Mol Sci,2017,18(6):1115.
[8] PETERLIN P,GASCHET J,GUILLAUME T,et al.FLT3 ligand plasma levels in acute myeloid leukemia[J].Haematologica,2019,104(6):e240-e243.
[9] O'DONNELL M R,TALLMAN M S,ABBOUD C N,et al.Acute myeloid leukemia,version 3.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(7):926-957.
[10] KAYSER S,LEVIS M J.Clinical implications of molecular markers in acute myeloid leukemia[J].Eur J Haematol,2019,102(1):20-35.
[11] 张道玉,袁小青,颜晗,等.急性髓系白血病化疗效果和预后影响因素的研究进展[J].中南医学科学杂志,2015(4):457-463.
[12] 黄韵映,上官辉,汪包珍.化学法提取贮存骨髓涂片DNA检测Fms样酪氨酸激酶3基因突变预测急性髓系白血病患者预后[J].白血病·淋巴瘤,2017,26(5):272-275.
[13] KAINZ B,FONATSCH C,SCHWARZINGER I,et al.Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia[J].Haematologica,2015,90(5):695-696.
[14] ADNAN-AWAD S,GABER O,ELTOKHY S A,et al.FLT3-ITD mutations in egyptian patients of acute myeloid leukemia:correlation with cytogenetic, FAB subgroups and prognosis[J].Clin Lab,2017,63(5):1027-1034.
[15] HU X,CHEN F.Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia[J].Hematology,2019,24(1):651-660.
[16] 周萌,储小玲,薛胜利,等.FLT3抑制剂在急性髓系白血病中的研究进展[J].中华血液学杂志,2019,40(9):787-791.
[17] KAZI J U,RÖNNSTRAND L.FMS-like tyrosine kinase 3/FLT3:from basic science to clinical implications[J].Physiol Rev,2019,99(3):1433-1466.
[18] YUAN X,QIN X,WANG D,et al.Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients[J].Nat Commun,2019,10(1):2498.
[19] ZHOU C Z,WANG R F,CHENG D L,et al.FLT3/FLT3L-mediated CD103(+) dendritic cells alleviates hepatic ischemia-reperfusion injury in mice via activation of treg cells[J].Biomed Pharmacother,2019,118:109031.
[20] RAMOS M I,TAK P P,LEBRE M C.Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation[J].Autoimmun Rev,2014,13(2):117-124.
[21] THORNE A H,MALO K N,WONG A J,et al.Adjuvant screen identifies synthetic dna-encoding flt3l and cd80 immunotherapeutics as candidates for enhancing anti-tumor T cell responses[J].Front Immunol,2020,11:327.
[22] MILNE P,WILHELM-BENARTZI C,GRUNWALD M R,et al.Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia[J].Blood Adv,2019,3(20):3052-3061.
[23] CAO T,JIANG N,LIAO H,et al.The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia[J].Sci Rep,2019,9(1):12209.
[24] HUANG Y,HU J,LU T,et al.Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis[J].Cancer Manag Res,2019,11:4129-4142.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 277671 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364